364 Index Name Paper ref. Name Paper ref. Ruiz, I Mon 390 Ruiz, JD Wed 109 Ruiz-Cabello, F Tue 123 Rumaks, J Mon 429, Tue 253, Wed 045 Rungby, J FC04.2.7, FC05.4.6, Tue 359, Tue 248 Ruohonen, ST W21.4, Thu 243 Ruohonen, S W21.4 Ruponen, M W21.3 Ruschitzka, FT FC16.1.2 Rusiecka, I Mon 181 Ruskoaho, H Tue 166 Rusli, I Thu 181 Russell, D Tue 145 Russell, FA Mon 287 Russell, R FC03.2.6 Russo, R FC18.1.6 Ruuskanen, JO Wed 088 Ruzic Zecevic, D Mon 039 Ryan, B Mon 453 Ryan, M Mon 314 Ryan, R Mon 052 Rysä, J W21.2, Tue 166 Saade, A Thu 055 Saarelainen, T Tue 339 Saarma, M Mon 341 Saastamoinen, LK Tue 363 Sabaté, M Tue 087 Sabbatini, P FC11.5.6 Sabetkasaei, M Wed 396 Sabo, AJ W34.4, Wed 321, Wed 435 Saboori, Mon 454 Sabra, AN Mon 372 Sabra, R Thu 247 Saccani, F Tue 258 Sadakata, Y Wed 115 Sadananda, P Mon 235 Saddichha, S FC01.4.6 Sadee, W FC14.2.5 Sadeghnia, HR Wed 364, Thu 342 Sadeghpour, B FC18.4.5 Sadikun, A FC16.3.4 Sædder, E Thu 413 Saegusa, H FC03.4.5 Saeki, M Wed 186 Saeki, Y Wed 414 Saenz-Rodríguez, MT Tue 409 Saenz-Rodriguez, R Wed 349 Saferis, V Tue 329 Safonts, L Tue 016 Sagdieva, GZ Thu 096 Sagot, P Tue 289, Tue 290 Sahebgharani, M Mon 454 Sahiner, M Mon 418 Sahin-Erdemli, I Mon 366 Sahnoun, R Mon 021 Saiful Yazan, L Tue 452 Saiko, P Thu 308 Sailler, L Tue 104 Saim, AH Mon 107 Sain-Guven, G Wed 249 Sainio, K Mon 215 Saint Raymond, A W36.1, W36.4 Sáinz, M Mon 130 Saito, A Wed 414 Saito, K Tue 201, Tue 311 Saito, M Thu 248 Saito, R Thu 108, Wed 223 Saito, Y Thu 319, Tue 320, Tue 459 Saito, Yusuke Thu 343 Sajedianfard, J Mon 085, Mon 088 Sakai, H Tue 234, Tue 259, Mon 304, Tue 287, Mon 303 Sakai, Y Thu 224 Sakai-Oshita, M Mon 304 Sakallý, E Mon 418 Sakamoto, K Tue 318, Tue 138, Wed 264 Sakanashi, M Thu 344, Thu 344 Sakata, D Tue 260, Tue 294 Sakata, R Tue 167 Sakata, S Tue 162 Sakoda, N Mon 386 Sakurada, T Wed 247 Sakurai, E Tue 163, FC03.4.5 Sakurai, E Thu 414 Sakurai, T Mon 386 Sakurai, Y Tue 163 Salahuddin, M Thu 345 Salari, A-A Wed 012 Salari, R Tue 052 Salas, CE Wed 302, Tue 428 Salatino, A Mon 040 Salazar, M Mon 123 Salazar, N Tue 164 Salcedo, MS Wed 352 Saldaña, HKR Thu 115 Saldiva, P Wed 231 Saleh Moqadam, M Tue 165 Salehi, A Thu 074 Salehi, M Tue 165 Salem, Z FC01.3.4 Salenius, J-P Thu 223 Salgueiro, L Tue 257 Saliba, F W02.2.6 Sallés, J Wed 046 Sallinen, J W01.3.3 Sallustio, B Tue 495 Salmasi, H Mon 099 Salmonsen, R Mon 264 Salonen, J Thu 170, Tue 032 Saloniemi, T Wed 446 Salouage, I FC07.3.6, Mon 020, Thu 346, Wed 348, Mon 021, Mon 004 Salter, M FC03.3.2 Salvesen Blix, H Mon 234 Salvicchi, A Mon 113 Samai, M Mon 157 Samarzija, I Thu 441 Sambo, X Thu 315 Samer, C Mon 337, Tue 166 Sammons, HM Thu 007 Samojlik, I Tue 167 Sampaio, C SS01.2 Sampaio, NG Wed 079 Sampaio, SC Mon 273, Wed 332, Wed 333, Wed 334 Sampayo, C Tue 207 Samper, S W16.6
Name Paper ref. Name Paper ref. Samudre, S Thu 110 SanAntonio, E Mon 254 Sánchez Calero, J Thu 347 Sánchez, A Thu 249, Mon 239 Sánchez, G W04.1.3 Sánchez-Ferrer, CF W08.3, Tue 134 Sánchez-López, A W13.3, Thu 022, Thu 203 Sanchez-Luque, JJ Mon 149 Sandberg, K YI.03 Sandberg, M FC06.2.5 Sandén, C Thu 047 Sander, T Wed 066 Sandholm, J Tue 429 Sandhu, H Thu 056 Sandor, K Tue 271, Tue 250, Mon 283 Sándor, K W19.3, Mon 106, Mon 110 Sandor, Z W02.2.7, Tue 466 Sándor, Z Mon 401 Sandow, S Mon 235 Sanguinetti, MC FC12.3.1, FC06.1.1 Sanjani, MS Thu 057 Sanjaya, KC Thu 181 Sanni, SJ Thu 058 Sano, S Tue 375 Sansilvestri-Morel, P Thu 273, Thu 274 Santana da Silva, J W31.3 Santana-Farré, R Tue 387, Tue 391, Tue 392 Santiago, E Tue 420 Santibañez, M Mon 390 Santio, N Tue 429 Santoro, V Thu 419 Santos Gomes, M Thu 236 Santos Sierra, S Thu 014 Santos-Silva, AJ Wed 211 Sanvarinda, Y Thu 305 Tue 277 Sanz, E FC10.1.2, Mon 254 Sanz, F FC04.4.6 Sanz, MJ W08.5, Thu 437 Saragoni, S Mon 120 Saraste, A Thu 243 Sarc, L Wed 178 Sári, R Tue 142, Tue 128, Tue 125 Sarinic, VM Tue 121 Sarkar, A Tue 196 Sarkar, J Wed 294 Sarkisyan, K Tue 176 Sarparanta, M Thu 170 Sartipy, P FC13.2.5, Tue 126 Sarwar, M Mon 395 Sarwar, U Wed 036 Sasaguri, T Tue 162 Sasaki, K Tue 154 Sasaki, Y Mon 313 Sasano, M Mon 402, Mon 112 Sasay, J Tue 145 Sasso, O FC18.1.6 Satara, SS Tue 237 Sathirakul, K Mon 357, Mon 355, Tue 341, Mon 334 Sato, A Thu 320 Sato, M Mon 395 Sato, M Thu 059 Sato, S Tue 265 Sato, Y Tue 435, Thu 250, Tue 132 Satoh, H W02.2.3, Tue 262, Tue 380 Satoh, M Thu 250 Satta, J Tue 166 Satterfield, S Wed 126 Saunders, D Tue 090 Savarirayan, R W03.7 Savchenko, A Tue 129 Savci, V Mon 156 Savenko, I Tue 472 Savic Vujovic, K Mon 114 Savineau, J-P Wed 293 Savolainen, K W21.3, Mon 425 Savontaus, E Thu 243, W21.4 Savopoulos, C Mon 143 Sawa, A Thu 402 Sawada, H Mon 424, Mon 464 Sawai, T Thu 248 Sawicka, J FC06.3.6 Sawicki, G FC06.3.6 Sayama, Y Tue 136 Sayyah, M Mon 455 Scaccianoce, S Thu 440 Scaglione, F W07.5, Thu 111 Scammells, P Thu 080 Scaramello, CBV Wed 232 Scaramello, C Tue 162 Scavone, C Mon 292 Scekic, J Tue 081 Schäfer, H-G FC07.3.1 Schäfer, R YI.02 Schaffer, C FC14.2.3 Schätzle, R Tue 214 Schautzer, A Mon 153 Scheepers, R Wed 226 Scheffer, I FC12.1.1 Schegg, K FC12.4.5 Scheinin, M W01.3.4, Wed 088, Thu 052, Wed 092, Thu 071, Thu 084, Schelstraete, P Mon 365, Tue 306 Schetler, GFX FC11.1.1 Scheuer, T FC12.2.4 Schiavo, G Tue 488, Mon 449 Schiesser, C Mon 214 Schiffers, P Thu 251 Schiffers, PMA Wed 287 Schiffrin, E PL20, W04.2.1 Schiltz, RL FC18.4.2 Schinabek, R Tue 099 Schini-Kerth, VB FC16.1.1, W04.2.3, W30.4, Wed 306, Wed 273, Wed 385 Schjøtt, J Mon 234 Schlossmann, J Wed 234 Schlueter, T FC18.2.6 Schmall, A Mon 059 Schmidt, H FC15.4.4 Schmidt, M Tue 242, Wed 095 Schmidt, SF Wed 447 Schmidt, WE FC05.3.1 Schmiedl, S Tue 314, Tue 131 Schmitz, O Mon 154 Schneeweiss, S FC04.1.4 Schneider, J FC11.4.2, W01.2.1 Schneider, M Wed 070, FC06.2.5 Schnuerch, M Mon 217 Index 365
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307:
FC16 Natural products: Past and fut
- Page 308 and 309:
FC16 Natural products: Past and fut
- Page 310 and 311:
FC16 Natural products: Past and fut
- Page 312 and 313:
FC17 New approaches and targets in
- Page 314 and 315:
FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor